that occurs in PNH when used over 12 weeks as a first-line therapy in patients who hadn't been treated with Soliris (eculizumab) or Alexion's follow-up drug Ultomiris (ravulizumab). Iptacopan has ...

The Swiss pharma group said this morning that the top-line results of the APPOINT-PNH trial showed that iptacopan provided ... Alexion’s Soliris (eculizumab) and Ultomiris (ravulizumab).

9 Risitano AM, Röth A, Soret J, et al. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open ...

Novartis Canada is pleased to announce that Fabhalta® (iptacopan capsules) is now available across Canada for adult patients ...